AD/PD™ 2023 Alzheimer's & Parkinson's Diseases Conference

Mary Hamby, Ph.D. will present a poster titled "Pharmacodynamic Effects of the S2R Modulator CT1812 in Alzheimer’s Disease (AD) Patients Observed in a Meta-analysis of CSF Proteomes from SPARC and SHINE Part A" that will describe results of a proteomic biomarker meta-analysis of CSF samples from the Phase 2 SHINE and Phase 1b SPARC (studies with mild-to-moderate Alzheimer's disease who were treated with either CT1812 or placebo.
In addition, Lisa Ricciardi, CEO of Cognition Therapeutics will be participating in a panel hosted by the Alzheimer’s Drug Discovery Foundation. The panel, “Emerging Solutions: Novel Approaches to Alzheimer’s Disease” will take place on March 29, 2023 at 11:40am local time.

Gothenburg, Sweden

Event Details